- Home
- VNDA vs CTNM Comparison
VNDA vs CTNM Comparison
Compare VNDA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- CTNM
- Stock Information
- Founded
- VNDA 2002
- CTNM 2009
- Country
- VNDA United States
- CTNM United States
- Employees
- VNDA N/A
- CTNM N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- VNDA Health Care
- CTNM
- Exchange
- VNDA Nasdaq
- CTNM Nasdaq
- Market Cap
- VNDA 249.4M
- CTNM 248.7M
- IPO Year
- VNDA 2006
- CTNM 2024
- Fundamental
- Price
- VNDA $4.51
- CTNM $12.36
- Analyst Decision
- VNDA Strong Buy
- CTNM Strong Buy
- Analyst Count
- VNDA 2
- CTNM 4
- Target Price
- VNDA $16.50
- CTNM $22.75
- AVG Volume (30 Days)
- VNDA 404.6K
- CTNM 278.0K
- Earning Date
- VNDA 11-05-2025
- CTNM 11-05-2025
- Dividend Yield
- VNDA N/A
- CTNM N/A
- EPS Growth
- VNDA N/A
- CTNM N/A
- EPS
- VNDA N/A
- CTNM N/A
- Revenue
- VNDA $203,467,000.00
- CTNM N/A
- Revenue This Year
- VNDA $15.45
- CTNM N/A
- Revenue Next Year
- VNDA $37.82
- CTNM N/A
- P/E Ratio
- VNDA N/A
- CTNM N/A
- Revenue Growth
- VNDA 11.78
- CTNM N/A
- 52 Week Low
- VNDA $3.81
- CTNM $3.35
- 52 Week High
- VNDA $5.55
- CTNM $20.30
- Technical
- Relative Strength Index (RSI)
- VNDA 46.90
- CTNM 73.06
- Support Level
- VNDA $4.54
- CTNM $10.30
- Resistance Level
- VNDA $4.64
- CTNM $13.26
- Average True Range (ATR)
- VNDA 0.15
- CTNM 1.04
- MACD
- VNDA -0.01
- CTNM 0.03
- Stochastic Oscillator
- VNDA 8.89
- CTNM 77.13
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.